查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1416345

KRAS 抑制剂市场报告：2030 年趋势、预测和竞争分析

KRAS Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

KRAS 抑制剂的趋势和预测

预计2024年至2030年全球KRAS抑制剂市场将以32.5%的复合年增长率成长。该市场的主要驱动力是不同类型癌症中KRAS突变的盛行率不断增加、正在进行的临床试验数量的快速增加以及对精准医疗和个人化癌症治疗的投资的增加。全球KRAS抑制剂市场前景广阔，临床实验室、癌症诊断中心、医院、癌症研究机构和学术机构市场充满机会。

KRAS抑制剂市场洞察

Lucintel 预测，由于肺癌患者 KRW 突变盛行率急剧上升，以及人们对肺癌治疗研究的关注度增加，肺癌在预测期内将经历最高增长。

由于临床研究的增加以及研究机构和生物技术公司之间合作伙伴关係的扩大，癌症研究机构将继续成为该市场的最大部分。

由于癌症发生率高且该地区有主要企业，北美在整个预测期内可能仍然是最大的地区。

常问问题

Q1.市场成长预测是多少：

A1. 2024年至2030年，全球KRAS抑制剂市场预计将以32.5%的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 该市场的主要驱动力是不同癌症类型中 KRAS 突变的流行、正在进行的临床试验数量的快速增加以及对精准医疗和个性化癌症治疗的投资的增加。

Q3.市场的主要细分市场是：

A3. 全球KRAS抑制剂市场前景广阔，临床实验室、癌症诊断中心、医院、癌症研究机构和学术机构市场充满机会。

Q4.市场的主要企业是：

A4. 一些主要的 KRAS 抑制剂公司是：

  • Amgen
  • Boehringer Ingelheim
  • Bridgebio Pharma
  • Erasca
  • Innovent Biologics
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology

Q5.未来最大的细分市场是什么？

A5.Lucintel 预测，由于肺癌患者中 KRW 突变的盛行率急剧上升，人们越来越关注肺癌治疗方法的研究，肺癌将在预测期内经历最高的增长。

Q6.未来五年预计哪些地区的市场成长最大？

答：由于癌症发生率高且主要企业在该地区的存在，北美在整个预测期内仍将是最大的地区。

Q7. 可以客製化报告吗？

A6. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球 KRAS 抑制剂市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球KRAS抑制剂市场趋势（2018-2023）与预测（2024-2030）
  • 按癌症类型分類的全球 KRAS 抑制剂市场
    • 肺癌
    • 胰臟癌
    • 大肠直肠癌
    • 其他的
  • 全球 KRAS 抑制剂市场（按最终用途）
    • 临床实验室
    • 癌症诊断中心
    • 医院
    • 癌症研究组织
    • 学术机构
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球KRAS抑制剂市场区域分布
  • 北美KRAS抑制剂市场
  • 欧洲KRAS抑制剂市场
  • 亚太地区 KRAS 抑制剂市场
  • 其他地区KRAS抑制剂市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按癌症类型分類的全球 KRAS 抑制剂市场成长机会
    • 全球 KRAS 抑制剂市场成长机会（以最终用途）
    • 全球 KRAS 抑制剂市场成长机会（按地区）
  • 全球KRAS抑制剂市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球KRAS抑制剂市场产能扩张
    • 全球 KRAS 抑制剂市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Amgen
  • Boehringer Ingelheim
  • BridgeBio Pharma
  • Erasca
  • Innovent Biologics
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology
简介目录

KRAS Inhibitors Trends and Forecast

The future of the global KRAS inhibitors market looks promising with opportunities in the clinic laboratory, cancer diagnostic center, hospital, cancer research institute, and academic institution markets. The global KRAS inhibitors market is expected to grow with a CAGR of 32.5% from 2024 to 2030. The major drivers for this market are increasing prevalence of KRAS mutations in various types of cancer, surge in number of ongoing clinical trials, and growing investments in precision medicine and personalized cancer treatment.

A more than 150-page report is developed to help in your business decisions.

KRAS Inhibitors by Segment

The study includes a forecast for the global KRAS inhibitors by cancer type, end use, and region.

KRAS Inhibitors Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Others

KRAS Inhibitors Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Clinic Laboratories
  • Cancer Diagnostic Centers
  • Hospitals
  • Cancer Research Institutes
  • Academic Institutions
  • Others

KRAS Inhibitors Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of KRAS Inhibitors Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies KRAS inhibitors companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the KRAS inhibitors companies profiled in this report include-

  • Amgen
  • Boehringer Ingelheim
  • Bridgebio Pharma
  • Erasca
  • Innovent Biologics
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology

KRAS Inhibitors Market Insights

Lucintel forecasts that lung cancer is expected to witness highest growth over the forecast period due to surge in prevalence of KRW mutations in lung cancer patients and increasing focus towards research for lung cancer treatments.

Within this market, cancer research institutes will remain the largest segment due to the rising number of clinical research along with growing partnerships among research institutes and biotech companies.

North America will remain the largest region over the forecast period due to the high prevalence of cancer and presence of major players in the region.

Features of the Global KRAS Inhibitors Market

Market Size Estimates: KRAS inhibitors market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: KRAS inhibitors market size by cancer type, end use, and region in terms of value ($B).

Regional Analysis: KRAS inhibitors market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer types, end uses, and regions for the KRAS inhibitors market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the KRAS inhibitors market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for KRAS inhibitors market?

Answer: The global KRAS inhibitors market is expected to grow with a CAGR of 32.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the KRAS inhibitors market?

Answer: The major drivers for this market are increasing prevalence of KRAS mutations in various types of cancer, surge in number of ongoing clinical trials, and growing investments in precision medicine and personalized cancer treatment.

Q3. What are the major segments for KRAS inhibitors market?

Answer: The future of the global KRAS inhibitors market looks promising with opportunities in the clinic laboratory, cancer diagnostic center, hospital, cancer research institute, and academic institution markets.

Q4. Who are the key KRAS inhibitors market companies?

Answer: Some of the key KRAS inhibitors companies are as follows:

  • Amgen
  • Boehringer Ingelheim
  • Bridgebio Pharma
  • Erasca
  • Innovent Biologics
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology

Q5. Which KRAS inhibitors market segment will be the largest in future?

Answer: Lucintel forecasts that lung cancer is expected to witness highest growth over the forecast period due to surge in prevalence of KRW mutations in lung cancer patients and increasing focus towards research for lung cancer treatments.

Q6. In KRAS inhibitors market, which region is expected to be the largest in next 5 years?

Answer:North America will remain the largest region over the forecast period due to the high prevalence of cancer and presence of major players in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the KRAS inhibitors market by cancer type (lung cancer, pancreatic cancer, colorectal cancer, and others), end use (clinic laboratories, cancer diagnostic centers, hospitals, cancer research institutes, academic institutions, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global KRAS Inhibitors Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global KRAS Inhibitors Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global KRAS Inhibitors Market by Cancer Type
    • 3.3.1: Lung Cancer
    • 3.3.2: Pancreatic Cancer
    • 3.3.3: Colorectal Cancer
    • 3.3.4: Others
  • 3.4: Global KRAS Inhibitors Market by End Use
    • 3.4.1: Clinic Laboratories
    • 3.4.2: Cancer Diagnostic Centers
    • 3.4.3: Hospitals
    • 3.4.4: Cancer Research Institutes
    • 3.4.5: Academic Institutions
    • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global KRAS Inhibitors Market by Region
  • 4.2: North American KRAS Inhibitors Market
    • 4.2.2: North American KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
  • 4.3: European KRAS Inhibitors Market
    • 4.3.1: European KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
    • 4.3.2: European KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
  • 4.4: APAC KRAS Inhibitors Market
    • 4.4.1: APAC KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
    • 4.4.2: APAC KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others
  • 4.5: ROW KRAS Inhibitors Market
    • 4.5.1: ROW KRAS Inhibitors Market by Cancer Type: Lung Cancer, Pancreatic Cancer, Colorectal Cancer, and Others
    • 4.5.2: ROW KRAS Inhibitors Market by End Use: Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global KRAS Inhibitors Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global KRAS Inhibitors Market by End Use
    • 6.1.3: Growth Opportunities for the Global KRAS Inhibitors Market by Region
  • 6.2: Emerging Trends in the Global KRAS Inhibitors Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global KRAS Inhibitors Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global KRAS Inhibitors Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Amgen
  • 7.2: Boehringer Ingelheim
  • 7.3: BridgeBio Pharma
  • 7.4: Erasca
  • 7.5: Innovent Biologics
  • 7.6: Incyte
  • 7.7: Mirati Therapeutics
  • 7.8: Novartis
  • 7.9: Jemincare
  • 7.10: Cardiff Oncology